ncRNA basic information
ncRNA ID:
MI0000447/MI0000727
ncRNA Database:
miRBase
ncRNA Name:
miR-128
ncRNA Type:
miRNA
ncRNA Expression:
down-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
MAPK1
ncRNA Pathway:
MAPK signaling pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
the differentially expressed lncRNAs were screened based on microarray analysis. The expression of linc00161, miR-128 and MAPK1 in ovarian cancer-resistant tissues and cells was tested qRT-PCR, whereas MAPK1 protein expression was examined via western blot in the ovarian cancer resistant cells. The targeted relationship between miR-128 and linc00161 as well as the relationship between miR-128 and MAPK1 were testified by Dual luciferase gene reporter assay. The influence of miR-128 and MAPK1 on the proliferation of ovarian cancer-resistant cells was demonstrated by CCK-8 and colony formation assay. The effect of linc00161 on ovarian cancer was demonstrated by xenograft tumor model in vivo.
Drug Response:
resistant
Cancer basic information
Cancer:
ovarian cancer
Tissue/Cell:
tissue and cell line ( SKOV3, SKOV3/DDP,CoC1,CoC1/DDP )
Other information
Title:
Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1.
Journal:
Mol Carcinog
Published:
2019
PubMed ID:
30556928